



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Richard G. Vile et al. Art Unit : 1633  
Serial No. : 10/533,613 Examiner : Kelaginamane T. Hiriyanna  
Filed : January 30, 2006 Conf. No. : 6311  
Title : METHODS AND VECTORS FOR CONTROLLING GENE EXPRESSION

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicants request consideration of the references listed on the attached PTO-1449 form. A copy of a communication from a foreign patent office in a counterpart application is enclosed. The remaining references have previously been cited.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. Pursuant to 37 C.F.R. 1.97(e)(1), I, the undersigned, hereby certify that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated 14 December 2006, which is not more than three months prior to the filing of this statement. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 3-2-07

  
D. Marie Kube, Ph.D.  
Reg. No. 59,744

Fish & Richardson P.C.  
60 South Sixth Street, Suite 3300  
Minneapolis, MN 55402  
Telephone: (612) 335-5070  
Facsimile: (612) 288-9696  
60403060.doc

**CERTIFICATE OF MAILING BY FIRST CLASS MAIL**

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

March 2, 2007

Date of Deposit

Signature

Judith A. Wasilkus

Typed or Printed Name of Person Signing Certificate

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-444US1	Application No. 10/533,613
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Richard G. Vile et al.	
		Filing Date January 30, 2006	Group Art Unit 1633
<b>U.S. Patent Documents</b>			

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						

<b>Foreign Patent Documents or Published Foreign Patent Applications</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	AC	WO 00/14255	03/16/00	WIPO			
	AD	WO 01/21823	03/29/01	WIPO			
	AE						
	AF						
	AG						

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	AH	Hallenbeck et al., "A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma," <u>Human Gene Therapy</u> , 1999, 10:1721-1733
	AI	Maity and Solomon, "Both Increased Stability and Transcription Contribute to the Induction of the Urokinase Plasminogen Activator Receptor (uPAR) Message by Hypoxia," <u>Exp. Cell Res.</u> , 2000, 255:250-257
	AJ	Wang et al., "Posttranscriptional regulation of urokinase plasminogen activator receptor messenger RNA levels by leukocyte integrin engagement," <u>Proc. Natl. Acad. Sci. USA</u> , 1998, 95:6296-6301
	AK	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	